Outlook Therapeutics (OTLK) Total Non-Current Liabilities (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Total Non-Current Liabilities of $50.2 million for Q1 2026, up 8.85% year-over-year from $46.1 million in Q1 2025, and up 1.9% quarter-over-quarter from $49.2 million in Q4 2025.
Outlook Therapeutics (OTLK) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Total Non-Current Liabilities for 12 consecutive years, with $50.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 8.85% year-over-year to $50.2 million; the TTM figure through Mar 2026 stood at $50.2 million (up 8.85% YoY), while the FY2025 annual figure was $46.0 million, up 7.48% from the prior year.
- Total Non-Current Liabilities improved to $50.2 million in Q1 2026 per OTLK's latest filing, from $49.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $54.1 million in Q1 2024 and bottomed at $18.4 million in Q2 2022.
- Historically, Total Non-Current Liabilities has averaged $43.2 million across 5 years, with a median of $46.1 million in 2025.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 170.81% — and 2025, when it retreated 14.78%.
- Outlook Therapeutics' Total Non-Current Liabilities stood at $46.9 million in 2022, then retreated by 1.99% to $46.0 million in 2023, then gained by 5.44% to $48.5 million in 2024, then grew by 1.56% to $49.2 million in 2025, then climbed by 1.9% to $50.2 million in 2026.
- Business Quant data shows OTLK's Total Non-Current Liabilities at $50.2 million in Q1 2026, $49.2 million in Q4 2025, and $46.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | 28.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.16 Mn |
| Dec 31, 2025 | 49.23 Mn |
| Sep 30, 2025 | 46.00 Mn |
| Jun 30, 2025 | 52.13 Mn |
| Mar 31, 2025 | 46.09 Mn |
| Dec 31, 2024 | 48.47 Mn |
| Sep 30, 2024 | 42.80 Mn |
| Jun 30, 2024 | 42.81 Mn |
| Mar 31, 2024 | 54.08 Mn |
| Dec 31, 2023 | 45.97 Mn |
| Sep 30, 2023 | 46.73 Mn |
| Jun 30, 2023 | 49.93 Mn |
| Mar 31, 2023 | 43.53 Mn |
| Dec 31, 2022 | 46.90 Mn |
| Sep 30, 2022 | 19.73 Mn |
| Jun 30, 2022 | 18.44 Mn |
| Mar 31, 2022 | 31.43 Mn |
| Dec 31, 2021 | 29.58 Mn |
| Sep 30, 2021 | 17.68 Mn |
| Jun 30, 2021 | 19.70 Mn |